New drugs should be judged on “willingness to pay” basis, says leading economistBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c3899 (Published 19 July 2010) Cite this as: BMJ 2010;341:c3899
- Jacqui Wise
A leading economist has argued that “willingness to pay” is the best way to judge whether a new drug should be funded.
Peter Zweifel, professor of economics at the University of Zurich, said that the willingness to pay criterion—which assigns a value to health benefits by directly asking members of the public how much they would be prepared to pay to gain a benefit—is a better measure than quality adjusted life years (QALYs), the commonly used measure that combines an estimate of the life years gained from an intervention with a judgment on the quality of these life years.
Speaking at a seminar at the independent Office of Health Economics in London, Professor Zweifel said, “I would argue that the real gold standard in economic …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial